Notice of Change to Application Due Date for RFA-CA-19-045 "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)"

Notice Number: NOT-CA-20-056

Key Dates
Release Date: April 28, 2020

Related Announcements
RFA-CA-19-045

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to update applicants about a change of the second receipt date for RFA-CA-19-045, "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)".

This new receipt date (October 30, 2020) will allow applicants more time to prepare for applications given the delays and complications caused by the COVID-19 pandemic.

The following sections of the FOA are being modified:

Part 1. Overview Information, Key Dates

Currently reads

Application Due Dates(s): October 30, 2019; July 30, 2020

Modified to read (in italics)

Application Due Dates(s): October 30, 2019; October 30, 2020

Currently reads

Scientific Merit Review: January 2020; September 2020

Modified to read (in italics)

Scientific Merit Review: January 2020; January 2021

Currently reads

Advisory Council Review: May 2020; January 2021

Modified to read (in italics)

Advisory Council Review: May 2020; May 2021

Currently reads

Earliest Start Date: July 2020; April 2021

Modified to read (in italics)

Earliest Start Date: July 2020; July 2021

Currently reads

Expiration Date: July 31, 2020

Modified to read (in italics)

Expiration Date: October 31, 2020

All other aspects of RFA-CA-19-045 remain unchanged.

Inquiries

Please direct all inquiries to:

Leah E. Mechanic, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-6847
Email: NCI_PE-CGS@mail.nih.gov